Home > News > 20/Reductions in QRS area predict long-term clinical outcomes after cardiac resynchronisation therapy
Arrhythmia
Read Time: < 1 min

20/Reductions in QRS area predict long-term clinical outcomes after cardiac resynchronisation therapy

Published Online: October 2nd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr20
Authors: O Okafor (Presenting Author) - Aston University, Birmingham, UK; A Zegard - Aston University, Birmingham, UK; PM van Dam - University Medical Centre, Utrecht, The Netherlands; B Stegemann - Aston University, Birmingham, UK; T Qiu - Queen Elizabeth Hospital, Birmingham, UK; H Marshall - Queen Elizabeth Hospital, Birmingham, UK; F Leyva - Aston University, Birmingham, UK
Quick Links:
Article
Article Information
Article:

Background: Some studies have shown that pre-implantation QRS area (QRSarea) predicts clinical outcomes after cardiac resynchronisation therapy (CRT).

Objective: To determine whether post-implantation changes in QRSarea predicts clinical outcomes after CRT.

Methods: In this retrospective study, QRSarea, derived from pre- and post-implantation vectorcardiography (VCG), were assessed in relation to the primary endpoint of cardiac mortality after CRT. Other endpoints included total mortality, total mortality or heart failure (HF) hospitalisation and total mortality or major adverse cardiac events (MACE).

Results: In patients (n=380, age 72.0 ± 12.4 years, 68.7% male) undergoing CRT over 7.7 years (median follow-up: 3.8 years [interquartile range 2.3–5.3]), pre-implantation QRSarea ≥ 102 µVs predicted cardiac mortality (HR: 0.36; p < 0.001) as well as total mortality (0.58; p=0.001), total mortality or HF hospitalisation (HR: 0.53) and total mortality or MACE (HR: 0.52) (both p < 0.001). The association of QRSarea with cardiac mortality was independent of known confounders, including QRS duration (QRSd) and morphology (p<0.001). After CRT, a reduction in QRSarea ≥ 45 µVs or any reduction in QRSd predicted cardiac mortality (area under curve: 0.74 and 0.72, respectively; p = 0.425 for comparison). Concomitant reductions in QRSarea and QRSd were the best predictor of cardiac mortality (HR: 0.12; p <0.001 for interaction).

Conclusion: Pre-implantation QRSarea, derived from VCG, was superior to QRSd and LBBB in predicting cardiac mortality after CRT. A post-implant reduction in both QRSarea and QRSd was associated with the best outcomes.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72